US4521593A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for obtaining lacto-N-norhexaosyl ceramide
Assignee: Laboratoire Lucchini SA
•
Filing: 1982-12-15
•
Granted: 1985-06-04
•
Expires: 2002-12-15
Abstract
Abstract From human placental tissue, gangliosides and lacto-N-norhexaosyl ceramide of formula: Galβl→4GlcNAcβl→3Galβl→4GlcNAcβl.f wdarw.3Galβl→4Glc→(ceramide) are successively extracted. Lacto-N-norhexaosyl ceramide is used in the diagnosis and treatment of certain tumors and autoimmune diseases.
Inventors
- 👤 Michel Martin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 06:22
CPC Classifications
C; C07; C07H; C07H15/00; C07H15/02; C07H15/04; C07H15/10; A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K35/00; A61K35/12; A61K35/48; A61K35/50
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
57 words
A process for obtaining lacto-N-norhexaosyl ceramide of formula: Galβ1→4GlcNAcβ1→3Galβ1→4GlcNAcβ1.fwdarw.3Galβ1→4Glc→Cer, from raw gangliosides isolated from human placental tissue dissolved in an organic solvent wherein the gangliosides are precipitated therefrom by adding ethyl acetate, the impurities remaining in the organic solvent and separating the purified gangliosides, containing in approximately equal proportions sialyl esters of hematoside, paragloboside and lacto-N-norhexaosyl ceramide.
Claim 2
Dependent Claim
57 words
A process for obtaining lacto-N-norhexaosyl ceramide of formula: Galβ1→4GlcNAcβ1→3Galβ1→4GlcNAcβ1.fwdarw.3Galβ1→4Glc→Cer, from raw gangliosides isolated from human placental tissue dissolved in an organic solvent wherein the gangliosides are precipitated therefrom by adding ethyl acetate, the impurities remaining in the organic solvent and separating the purified gangliosides, containing in approximately equal proportions sialyl esters of hematoside, paragloboside and lacto-N-norhexaosyl ceramide.
Claim 3
Dependent Claim
37 words
A process according to claim 1, wherein the separated mixture of sialyl esters is purified by hydrolysis of said sialyl esters of hematoside, paragloboside and lacto-N-norhexaosyl ceramide and separating from the hydrolysis mixture substantially pure lacto-N-norhexaosyl ceramide.
Claim 4
Dependent Claim
25 words
A process according to claim 1, wherein the ethyl acetate is added in a ratio of approximately 8.5 times the volume of the organic solvent.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-06-03 | 1988-12-03 | 1989-06-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-06-03 | 1992-12-03 | 1993-06-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-06-03 | 1996-12-03 | 1997-06-04 | $7700.00 | Window Closed / Lapsed |